Perimeter Medical Imaging AI (PINK) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
15 May, 2026Opening remarks and agenda
Meeting opened with a welcome and explanation of virtual procedures, including voting and question protocols.
Notice of meeting, agenda, and proxy instruments were distributed to shareholders on November 13, 2024.
Quorum was established with 27 shareholders representing 43.23% of issued shares present or by proxy.
Board and executive committee updates
Nominations for directors included Suzanne M. Foster, Aaron Davidson, Ian Mortimer, Joshua G. Vose, and Adrian Mendes.
No advance notice of other director nominations was received.
All nominated directors were elected to serve until the next annual meeting or until successors are appointed.
Overview of voting outcomes
All motions, including director elections and auditor appointment, were passed with sufficient votes.
KPMG LLP was appointed as auditor for the ensuing year, with the board authorized to fix remuneration.
Meeting was formally concluded following a motion to terminate.
Latest events from Perimeter Medical Imaging AI
- Directors elected, auditor reappointed, and equity incentive plan expanded by shareholder vote.PINK
AGM 202515 May 2026 - FDA-approved AI imaging device launches commercialization, targeting rapid market expansion.PINK
2026 Bloom Burton & Co. Healthcare Investor Conference21 Apr 2026 - Record revenue growth and FDA approval for Claire OCT mark a pivotal year of transformation.PINK
Q4 20252 Apr 2026 - AI-powered imaging platform drives better cancer surgery outcomes and scalable recurring revenue.PINK
Investor presentation25 Mar 2026 - AI-powered OCT imaging is transforming surgical outcomes and driving commercial growth.PINK
Investor Update3 Feb 2026 - Revenue up 83% YoY, net loss down 35%, and pivotal B-Series OCT trial ahead of schedule.PINK
Q2 20241 Feb 2026 - Q3 revenue up 142% as S-Series OCT gains traction; pivotal B-Series trial completed.PINK
Q3 202414 Jan 2026 - Pivotal trial met its endpoint, paving the way for FDA submission and commercial launch in 2025.PINK
Status Update13 Jan 2026 - AI-powered imaging device reduces cancer surgery re-operations and drives recurring revenue.PINK
Small Cap Growth Virtual Investor Conference 202529 Dec 2025